CJC-1295 vs tesamorelin: how the two peptides differ

Last updated 2026-07-26

What are CJC-1295 and tesamorelin, and how are they related?

Both molecules are synthetic analogues of growth hormone-releasing hormone (GHRH), the 44-amino-acid hypothalamic peptide that tells the pituitary to release growth hormone. They share the same starting point but were engineered for different jobs. Tesamorelin is a stabilized 44-amino-acid GHRH analogue with an added trans-3-hexenoic acid group at the N-terminus, which slows its enzymatic breakdown. It was developed by Theratechnologies and approved by the FDA in 2010 under the brand name Egrifta, specifically for reducing excess abdominal fat in HIV patients with lipodystrophy ^[1]. It has since gone through additional approvals, including a longer-acting formulation, Egrifta SV, and a version studied in NASH. CJC-1295 is a shorter, modified GHRH fragment (amino acids 1-29 of GHRH) with several substitutions designed to resist enzymatic degradation, plus an optional Lys-maleimidopropionic acid (DAC) tag that lets it bind covalently to albumin in the blood ^[2]. That DAC tag is the whole story of CJC-1295's half-life advantage, and it's also the point of maximum confusion for people comparing the two peptides, so it gets its own section below. Neither drug is growth hormone itself. Both work upstream, prompting the pituitary to make and release its own GH in a pulsatile pattern, which is the theoretical selling point over injecting recombinant HGH directly.

Is CJC-1295 FDA approved like tesamorelin is?

No. Tesamorelin is FDA-approved for a specific indication (HIV-associated lipodystrophy) and carries an FDA label with dosing, warnings, and manufacturing standards behind it ^[1]. CJC-1295 has no FDA approval for any human indication. It's sold in the US almost exclusively as a research chemical, meaning it's intended for laboratory or research use, not for injection into humans, under FDA and DEA research-use frameworks that apply to unapproved substances ^[3]. This is not a small technicality. An approved drug has gone through Phase 1 through Phase 3 trials establishing safety and efficacy for a defined population, has an FDA-reviewed manufacturing process, and gets ongoing pharmacovigilance. CJC-1295 has none of that infrastructure. The clinical literature on it consists mainly of one industry-sponsored pharmacokinetic and pharmacodynamic study in healthy adults, published in 2006, which found that CJC-1295 with DAC significantly increased plasma GH and IGF-1 levels for at least 6 to 11 days after a single dose ^[4]. That's a real finding, but it's a PK/PD study in a small number of subjects, not an outcomes trial like the ones behind tesamorelin's approval. If you're trying to figure out how sourcing actually works for something with no approved medical use, the how to get CJC-1295 page walks through the research-use landscape honestly.

How do CJC-1295 and tesamorelin compare on dosing and half-life?

This is where the DAC distinction really matters. Tesamorelin's modification is about resisting the enzyme DPP-4, giving it a half-life long enough for once-daily subcutaneous dosing. The approved regimen is 2 mg by subcutaneous injection once daily ^[1]. CJC-1295 comes in two versions that get lumped together constantly: | Feature | CJC-1295 with DAC | CJC-1295 without DAC (also sold as "Mod GRF 1-29") | Tesamorelin |

What does the actual clinical evidence show for each?

Tesamorelin's evidence base is built on multiple randomized, placebo-controlled trials. In two key 26-week trials with over 800 combined HIV-positive participants, tesamorelin reduced visceral adipose tissue (VAT) by about 15-18% relative to placebo and improved triglycerides, with the FDA label citing statistically significant VAT reduction as the primary endpoint ^[1][5]. A later extension study also examined a lower-frequency, higher-concentration formulation (Egrifta SV) for similar effect with less injection volume. CJC-1295's evidence is thinner and mostly mechanistic. The key study, Teichman et al. (2006) in the Journal of Clinical Endocrinology & Metabolism, gave single and multiple doses of CJC-1295 (with DAC) to healthy adults and measured GH and IGF-1 pharmacokinetics, not body composition or clinical outcomes ^[4]. It found mean GH levels increased 2- to 10-fold depending on dose, and IGF-1 stayed elevated 2- to 3-fold above baseline for up to 9 to 11 days after a single 60-100 mcg/kg dose. That's a genuine physiological signal, but it answers 'does this raise GH and IGF-1' rather than 'does this reduce fat, build muscle, or improve any hard clinical outcome' the way tesamorelin's trials do. Everything past that point, fat loss claims, anti-aging claims, muscle-building claims for CJC-1295, comes from bodybuilding forums and anecdotal reports, not peer-reviewed trials. That distinction matters enormously if you're trying to make a decision based on evidence rather than momentum.

Do CJC-1295 and tesamorelin work the same way in the body?

Broadly yes, both bind the GHRH receptor on pituitary somatotrophs and stimulate GH synthesis and release, which then drives hepatic IGF-1 production. The downstream biology, GH pulsing, IGF-1 rise, effects on lipolysis and lean mass, is shared machinery. Where they diverge is exposure pattern and downstream regulation. Tesamorelin's shorter half-life (around 26-38 minutes) ^[1] combined with once-daily dosing produces a GH pulse that more closely resembles a natural nocturnal GH surge, which may be part of why its trials could isolate a clean VAT-reduction signal without dramatic tachyphylaxis. CJC-1295 with DAC produces sustained, non-pulsatile elevation of GH and IGF-1 for days at a time, which is a fundamentally different physiological pattern, and its long-term downstream effects on pituitary sensitivity or feedback inhibition are not well characterized in humans. Neither drug is a growth hormone secretagogue receptor (ghrelin receptor) agonist on its own. That's a different pharmacological class entirely, covered in the next section, because it's the piece of the puzzle that explains why CJC-1295 shows up paired with ipamorelin so often.

Why is CJC-1295 usually paired with ipamorelin, and does that combination matter for tesamorelin comparisons?

Ipamorelin is a ghrelin-receptor agonist (a GHRP, growth hormone releasing peptide), a completely different mechanism from GHRH analogues. GHRH analogues like CJC-1295 and tesamorelin increase the amplitude of GH pulses by acting on the GHRH receptor; ghrelin agonists like ipamorelin increase pulse frequency and amplitude by acting on a separate receptor (GHS-R1a) and by suppressing somatostatin, the hormone that normally puts the brakes on GH release. The rationale for stacking a GHRH analogue with a ghrelin agonist rests on older research showing GHRH and GHRP-class compounds can produce more-than-additive GH release when combined, because they act on different, complementary control points in the same axis ^[6]. That combined effect has been demonstrated for GH output in small studies combining GHRH with GHRPs generally. It has not been demonstrated as a body-composition or clinical outcome benefit specifically for the CJC-1295 plus ipamorelin combination in controlled human trials. Anyone telling you the combo is proven to build muscle or burn fat faster than either compound alone is repeating forum lore, not citing a study. Tesamorelin, by contrast, has never been studied in combination with a ghrelin agonist in its approval trials. It was tested and approved as monotherapy ^[1]. If someone's comparing 'CJC-1295 plus ipamorelin' against 'tesamorelin alone,' they're not comparing equivalent evidence tiers, one is an approved single-agent regimen with outcome data, the other is a two-peptide combination whose combined-effect claim is mechanistically plausible but clinically unproven for the specific pairing.

What are the approved and studied uses for each peptide?

Tesamorelin has one narrow, well-defined approved use: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, dosed at 2 mg subcutaneously once daily ^[1]. It has also been studied off-label in trials for non-HIV populations with visceral obesity and in a Phase 2 trial for non-alcoholic steatohepatitis (NASH), though those uses aren't part of the current approved label. CJC-1295 has zero approved uses. What exists is a single PK/PD study in healthy volunteers demonstrating GH and IGF-1 elevation ^[4], plus scattered older animal and cell-based mechanistic work on GHRH analogues generally. Everything beyond 'it raises GH and IGF-1 for days after a dose' is extrapolation, not established indication. This gap in evidence quality is the single most important thing to understand before choosing between them, and it's why regulatory bodies treat them so differently: one has cleared the bar of proving a specific clinical benefit outweighs specific risks in a defined population; the other hasn't been tested to that standard at all.

What are the side effects and safety profile of each?

Tesamorelin's label documents specific adverse effects from controlled trials: injection site reactions (erythema, pruritus) were the most common, along with arthralgia, peripheral edema, and myalgia. The label also carries warnings about potential for increased blood glucose (since GH antagonizes insulin action), the need to avoid use in patients with disrupted hypothalamic-pituitary axis activity or active malignancy, and a warning about hypersensitivity reactions, including at least one reported case of angioedema ^[1]. CJC-1295's known side effect profile is limited to what the small existing study observed, injection site reactions and flushing were reported in the Teichman 2006 trial ^[4], plus theoretical GH-class risks (fluid retention, joint pain, insulin resistance, and the general concern about unregulated exogenous GH-axis stimulation raising IGF-1 chronically). Because CJC-1295 hasn't gone through large controlled safety trials, rarer or longer-term risks simply aren't characterized the way they are for an approved drug. That's not proof it's dangerous; it's an evidence gap, and the honest answer is nobody has a solid denominator for how often serious adverse events occur with unsupervised, unregulated use. Anyone using either compound outside of tesamorelin's approved medical supervision should be tracking IGF-1 levels and glucose markers, because that's the physiological lever both peptides pull.

How does cost compare between CJC-1295 and tesamorelin?

Tesamorelin as the branded product Egrifta/Egrifta SV is expensive, list prices have historically run in the range of several thousand dollars per month before insurance or patient assistance programs, reflecting its status as a specialty biologic-adjacent peptide drug with orphan-adjacent pricing dynamics common to HIV-lipodystrophy treatments. Compounded tesamorelin, where available through a compounding pharmacy with a prescription, is typically far cheaper than the branded product, though compounded formulations aren't FDA-approved products themselves and vary by pharmacy. CJC-1295 sold as a research compound is priced per vial (commonly 2-5 mg vials) and costs are generally lower per unit than compounded tesamorelin, but there's no standardized quality or purity benchmark across suppliers the way there is for an FDA-approved drug or a state-licensed compounding pharmacy. Price alone tells you nothing about purity, sterility, or accurate labeling, and that gap is exactly where sourcing risk lives. If cost and sourcing quality are the actual question you're trying to answer, CJC-1295 for sale covers what to actually check before buying.

Which one should a researcher or patient actually consider?

If you have a diagnosed medical condition tesamorelin is approved for (HIV-associated lipodystrophy with excess visceral fat), tesamorelin is the only one of the two with FDA approval, physician-prescribable status, and trial-proven efficacy for that specific indication ^[1]. That's not a close call. For anyone considering CJC-1295 for any purpose, the honest framing is: this is a research compound with one small human PK study behind it, no approved indication, no long-term safety data, and a body of enthusiast claims that outruns the science by a wide margin. If you're going to use it anyway for research purposes, understanding correct handling matters more than most sourcing forums admit. Reconstitution technique, storage temperature, and injection site rotation all affect peptide stability and consistency far more than which supplier you picked. The CJC-1295 reconstitution guide, CJC-1295 injection sites guide, and CJC-1295 storage and shelf life page cover the practical mechanics that actually change outcomes. CJC-1295 Co exists because this space is full of noise and short on straight answers; the provider-reviewed sourcing route we point people to, fulfilled through a licensed pharmacy partner, is built around that gap between hype and evidence, not around promising results the data doesn't support.

How does the ipamorelin pairing change the tesamorelin comparison?

It doesn't change tesamorelin's evidence status at all, tesamorelin remains an approved single-agent drug regardless of what CJC-1295 is paired with. What it changes is the fairness of the comparison itself. When people say 'CJC-1295 works better than tesamorelin,' they are very often actually comparing a CJC-1295 plus ipamorelin stack against tesamorelin alone, which conflates two variables: the GHRH analogue choice and the addition of a second drug class entirely. A cleaner comparison would be CJC-1295 alone versus tesamorelin alone, and that comparison has essentially no head-to-head clinical trial data at all; both compounds have mostly been studied in isolation, in different populations, for different endpoints. Nobody has run a randomized trial putting CJC-1295 head-to-head against tesamorelin for the same outcome measure, so any claim that one 'beats' the other is not resting on direct comparative evidence, it's resting on inference across separate studies with different designs, populations, and endpoints.

Frequently asked questions

Is CJC-1295 the same drug as tesamorelin?

No. Both are GHRH analogues that stimulate the pituitary to release growth hormone, but they're chemically distinct molecules. Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy; CJC-1295 has no FDA approval and is sold as a research compound with a much smaller evidence base behind it.

Which has a longer half-life, CJC-1295 or tesamorelin?

CJC-1295 with DAC has the longer half-life by far, roughly 6-8 days versus tesamorelin's 26-38 minutes. CJC-1295 without DAC (Mod GRF 1-29) has a short half-life similar to tesamorelin's, around 30 minutes, because it lacks the albumin-binding DAC tag that extends exposure.

Can CJC-1295 be used instead of tesamorelin for visceral fat loss?

There's no controlled trial evidence that CJC-1295 reduces visceral fat the way tesamorelin's approval trials showed (roughly 15-18% VAT reduction versus placebo). Tesamorelin is the only one of the two proven for that specific outcome in humans; CJC-1295's human data is limited to a GH/IGF-1 pharmacokinetic study.

Is tesamorelin FDA approved and is CJC-1295 FDA approved?

Tesamorelin is FDA-approved under the brand names Egrifta and Egrifta SV for reducing excess abdominal fat in HIV patients with lipodystrophy. CJC-1295 has no FDA approval for any human use and is sold as a research chemical, not a prescribable drug.

What is the difference between CJC-1295 with DAC and without DAC?

DAC (Drug Affinity Complex) is a chemical tag that lets CJC-1295 bind albumin in blood, extending its half-life from about 30 minutes to roughly a week. No-DAC CJC-1295 (Mod GRF 1-29) clears quickly and mimics the body's natural short GHRH pulse; DAC version gives sustained, non-pulsatile elevation instead.

Why is CJC-1295 combined with ipamorelin?

Ipamorelin acts on a separate receptor (the ghrelin receptor) than CJC-1295's GHRH receptor pathway, and older research on GHRH plus GHRP combinations shows a more-than-additive GH release effect. That effect is documented for the GH signal itself, but no controlled trial has proven a specific clinical or body-composition benefit for the CJC-1295/ipamorelin pairing.

How much does tesamorelin cost compared to CJC-1295?

Branded tesamorelin (Egrifta) is expensive, often several thousand dollars monthly at list price before insurance or assistance programs, reflecting its specialty-drug status. Research-grade CJC-1295 is priced per vial and is typically cheaper per unit, but pricing says nothing about purity or quality without independent verification.

What side effects does tesamorelin have that CJC-1295 might share?

Tesamorelin's label lists injection site reactions, joint pain (arthralgia), muscle pain (myalgia), peripheral swelling, and a warning about blood sugar increases and hypersensitivity reactions. CJC-1295's limited study data reported injection site reactions and flushing; broader long-term risks aren't characterized due to lack of large trials.

Has anyone done a head-to-head clinical trial of CJC-1295 versus tesamorelin?

No direct randomized head-to-head trial exists comparing CJC-1295 to tesamorelin for the same outcome. Each has been studied separately, in different populations, for different endpoints, so any claim that one outperforms the other is inference across studies, not direct comparative evidence.

Is CJC-1295 legal to buy and use?

CJC-1295 is sold in the US as a research-use compound, not as an approved drug for human injection. It isn't a scheduled controlled substance, but using it outside of research settings falls outside its labeled purpose and outside FDA oversight that applies to approved medications.

Does CJC-1295 raise IGF-1 the same way tesamorelin does?

Both raise IGF-1 by stimulating GH release, but the pattern differs. Tesamorelin's approval trials measured IGF-1 changes as a secondary marker alongside its primary VAT-reduction endpoint. CJC-1295's 2006 PK study found IGF-1 stayed elevated 2 to 3 times above baseline for up to 9 to 11 days after a single dose.

What's the biggest evidence gap between these two peptides?

Tesamorelin has multiple randomized, placebo-controlled trials with hundreds of participants proving a specific clinical outcome (visceral fat reduction). CJC-1295's human evidence is essentially one pharmacokinetic study measuring hormone levels, not clinical outcomes, in healthy volunteers. That's a difference in evidence tier, more than dosing or mechanism.

Sources

1. FDA, Egrifta (tesamorelin) prescribing information: Tesamorelin is FDA-approved for reduction of excess abdominal fat in HIV patients with lipodystrophy, dosed at 2 mg daily, with documented side effects and half-life
2. NIH PubChem, CJC-1295 compound summary: CJC-1295 structure as a modified GHRH(1-29) analogue and its DAC (albumin-binding) modification
3. FDA, Research Use Only guidance framework: Unapproved research chemicals are distinct from FDA-approved drugs and fall outside standard drug manufacturing and labeling oversight
4. Teichman SL, et al., Journal of Clinical Endocrinology & Metabolism (2006): Single and multiple dose CJC-1295 with DAC significantly increased GH and IGF-1 for up to 6-11 days after dosing in healthy adults
5. Falutz J, et al., New England Journal of Medicine (2007), tesamorelin lipodystrophy trial: Tesamorelin significantly reduced visceral adipose tissue compared to placebo in HIV-associated lipodystrophy trials
6. NCBI Bookshelf/Endotext, Growth Hormone Releasing Hormone and Growth Hormone Secretagogues physiology: GHRH analogues and ghrelin-receptor agonists (GHRPs) act on separate receptors and can produce more-than-additive GH release when combined